Mouse models of pediatric high-grade gliomas with MYCN amplification reveal intratumoral heterogeneity and lineage signatures
Standard
Mouse models of pediatric high-grade gliomas with MYCN amplification reveal intratumoral heterogeneity and lineage signatures. / Schoof, Melanie; Godbole, Shweta; Albert, Thomas K; Dottermusch, Matthias; Walter, Carolin; Ballast, Annika; Qin, Nan; Olivera, Marlena Baca; Göbel, Carolin; Neyazi, Sina; Holdhof, Dörthe; Kresbach, Catena; Peter, Levke-Sophie; Epplen, Gefion Dorothea; Thaden, Vanessa; Spohn, Michael; Blattner-Johnson, Mirjam; Modemann, Franziska; Mynarek, Martin; Rutkowski, Stefan; Sill, Martin; Varghese, Julian; Afflerbach, Ann-Kristin; Eckhardt, Alicia; Münter, Daniel; Verma, Archana; Struve, Nina; Jones, David T W; Remke, Marc; Neumann, Julia E; Kerl, Kornelius; Schüller, Ulrich.
in: NAT COMMUN, Jahrgang 14, Nr. 1, 24.11.2023, S. 7717.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Mouse models of pediatric high-grade gliomas with MYCN amplification reveal intratumoral heterogeneity and lineage signatures
AU - Schoof, Melanie
AU - Godbole, Shweta
AU - Albert, Thomas K
AU - Dottermusch, Matthias
AU - Walter, Carolin
AU - Ballast, Annika
AU - Qin, Nan
AU - Olivera, Marlena Baca
AU - Göbel, Carolin
AU - Neyazi, Sina
AU - Holdhof, Dörthe
AU - Kresbach, Catena
AU - Peter, Levke-Sophie
AU - Epplen, Gefion Dorothea
AU - Thaden, Vanessa
AU - Spohn, Michael
AU - Blattner-Johnson, Mirjam
AU - Modemann, Franziska
AU - Mynarek, Martin
AU - Rutkowski, Stefan
AU - Sill, Martin
AU - Varghese, Julian
AU - Afflerbach, Ann-Kristin
AU - Eckhardt, Alicia
AU - Münter, Daniel
AU - Verma, Archana
AU - Struve, Nina
AU - Jones, David T W
AU - Remke, Marc
AU - Neumann, Julia E
AU - Kerl, Kornelius
AU - Schüller, Ulrich
N1 - © 2023. The Author(s).
PY - 2023/11/24
Y1 - 2023/11/24
N2 - Pediatric high-grade gliomas of the subclass MYCN (HGG-MYCN) are highly aggressive tumors frequently carrying MYCN amplifications, TP53 mutations, or both alterations. Due to their rarity, such tumors have only recently been identified as a distinct entity, and biological as well as clinical characteristics have not been addressed specifically. To gain insights into tumorigenesis and molecular profiles of these tumors, and to ultimately suggest alternative treatment options, we generated a genetically engineered mouse model by breeding hGFAP-cre::Trp53Fl/Fl::lsl-MYCN mice. All mice developed aggressive forebrain tumors early in their lifetime that mimic human HGG-MYCN regarding histology, DNA methylation, and gene expression. Single-cell RNA sequencing revealed a high intratumoral heterogeneity with neuronal and oligodendroglial lineage signatures. High-throughput drug screening using both mouse and human tumor cells finally indicated high efficacy of Doxorubicin, Irinotecan, and Etoposide as possible therapy options that children with HGG-MYCN might benefit from.
AB - Pediatric high-grade gliomas of the subclass MYCN (HGG-MYCN) are highly aggressive tumors frequently carrying MYCN amplifications, TP53 mutations, or both alterations. Due to their rarity, such tumors have only recently been identified as a distinct entity, and biological as well as clinical characteristics have not been addressed specifically. To gain insights into tumorigenesis and molecular profiles of these tumors, and to ultimately suggest alternative treatment options, we generated a genetically engineered mouse model by breeding hGFAP-cre::Trp53Fl/Fl::lsl-MYCN mice. All mice developed aggressive forebrain tumors early in their lifetime that mimic human HGG-MYCN regarding histology, DNA methylation, and gene expression. Single-cell RNA sequencing revealed a high intratumoral heterogeneity with neuronal and oligodendroglial lineage signatures. High-throughput drug screening using both mouse and human tumor cells finally indicated high efficacy of Doxorubicin, Irinotecan, and Etoposide as possible therapy options that children with HGG-MYCN might benefit from.
KW - Humans
KW - Child
KW - Mice
KW - Animals
KW - N-Myc Proto-Oncogene Protein/genetics
KW - Neuroblastoma/metabolism
KW - Disease Models, Animal
KW - Glioma/genetics
KW - Mutation
KW - Gene Amplification
U2 - 10.1038/s41467-023-43564-w
DO - 10.1038/s41467-023-43564-w
M3 - SCORING: Journal article
C2 - 38001143
VL - 14
SP - 7717
JO - NAT COMMUN
JF - NAT COMMUN
SN - 2041-1723
IS - 1
ER -